15 research outputs found
Correction to: Incidental lowering of otitis-media complaints in otitis-prone children during COVID-19 pandemic: not all evil comes to hurt (European Journal of Pediatrics, (2020), 10.1007/s00431-020-03747-9)
No full textThe family name of the co-author of the article mentioned above was incorrectly spelled
Enantioselective construction of new heterocyclic scaffolds via organocatalyzed cascade reactions
No full text2017 - 2018Chirality plays a vital role in human daily life. After the famous but tragic case regarding the Thalidomide, Food and Drug Administration (FDA) gave a guide in relation to the submission of new drug applications... [edited by Author]XXXI cicl
Trajectories through the intertextual paths of Sumido en Verde Temblor : towards a description of a territorial author’ reading and writing practices
No full textFil: De Campos, Yanina Fátima. Universidad Nacional de Misiones. Facultad de Humanidades y Ciencias Sociales; Argentina.La intertextualidad se presta al juego creativo de autor como una forma provocativa y seductora del lenguaje literario; al mismo tiempo, se (re)presenta en nuestros recorridos de análisis críticos y refl exivos de la escritura de Rodolfo Nicolás Capaccio. Sumido en verde temblor –mapa y no frontera estable- murmura ecos de otras voces interculturales que nos sugieren describir las prácticas de lectura y escritura de su autor territorial, relacionadas con la tópica de la “Conquista” y el “Descubrimiento” de América. Además, propone una entrada posible a su polifacético proyecto estético y a su particular archivo de escritor en construcción.
En este sentido, mediante el continuo afán de refractar nuestro deseo en diálogo perpetuo con el de los lectores, buscamos recorrer un trayecto de difusión y transferencia que nos permita avanzar en nuestro trabajo como investigadores de la Universidad pública. Con ello, intentamos situar y desplazar en escena la libertad del significante que se despliega en toda nueva lectura y escritura reflexiva y que busca desencadenar un nuevo Texto capaz de de-escribir la práctica de la escritura (Cfr. Barthes, 2002: 106-108).Intertextuality lends itself to the author’s creative play as a provocative and seductive form of literary language; at the same time, it is (re)presented in our tour through the critical and refl ective analysis of Rodolfo Nicolás Capaccio’s writing. Sumido en verde temblor –map, not a steady frontier–, murmurs echoes of other intercultural voices that suggest us to describe its territorial author’ practices of reading and writing, which are related to the topic of the “Conquest” and “Discovery” of America. In addition, it proposes a possible entry to the author´s multifaceted/versatile aesthetic project and to his particular archive of writer under construction. In this sense, through the constant ambition to refract our desire in perpetual dialogue with that of the readers, we seek to follow a path of diff usion/dissemination and transference that allows us to advance in our work as researchers of the public university. With this, we try to situate and move on the scene the signifi er’s freedom that unfolds in every new reading and refl ective writing that seeks to trigger a new Text capable of de writing the practice of writing (Barthes, 2002: 106- 108)
Manifestaciones de la cultura emblemática del Barroco en Navarra: fray Félix Bretos y El menor predicador capuchino
No full textManifestaciones de la cultura emblemática del Barroco en Navarra: fray Félix
Bretos y El menor predicador capuchino
El capuchino Félix Bretos de Pamplona (Pamplona, h. 1621-1701), es autor
de El Menor Predicador Capuchino, sermonario con el que ingresa de lleno
en la nómina de los singulares predicadores de la Provincia. Para componer
su obra, recurre a un auténtico arsenal de erudición, con citas a las Sagradas
Escrituras, a los Padres de la Iglesia y a los escolásticos medievales, así como a
los autores grecolatinos y a otros más cercanos a su tiempo. Y entre sus muy
variadas fuentes se encuentra también la literatura emblemática, de manera
que asoman a las páginas de El Menor Predicador Capuchino ejemplos tomados de Alciato, Valeriano, Capaccio, Cartari, Camerarius o Saavedra Fajardo,
además de las fábulas de Esopo. Pero el texto no actúa únicamente como mero
receptor de referencias emblemáticas, sino que se convierte en sí mismo en un
libro de emblemas, por cuanto organiza cada uno de sus discursos como si de
un emblema se tratase, ajustado al esquema propugnado por Alciato que desarrolla lema, pictura y suscriptio. Por todo ello, autor y obra se convierten en una
excepcional manifestación de la cultura emblemática del Barroco en NavarraManifestations of the Baroque Emblematic Culture in Navarre: Brother Félix Bretos and El Menor Predicador Capuchino
The Capuchin Felix Bretos of Pamplona (Pamplona, at about 1621-1701),
is the author of El Menor Predicador Capuchino, a book of sermons thanks
to which he enters in the list of the singular preachers of the Province. To
compose his work he resorts to an authentic arsenal of erudition, with quotations from the Holy Scripture, the Fathers of the Church, and the medieval
scholastics, as well as from the Greco-Latin authors and other ones closer to
his age. And emblematic literature also appears among his very diverse sources,
so that in the pages of El Menor Predicador Capuchino examples from Alciato,
Valeriano, Capaccio, Cartari, Camerarius or Saavedra Fajardo are shown, as
well as Esopo’s fables. Nevertheless, the text not only works as a mere receiver
of emblematic references, but also becomes itself a book of emblems, as it organizes each one of its speechs as if it was an emblem, according to the schema
advocated of Alciato, that develops lemma, pictura and suscriptio. That is why
author and work become an exceptional manifestation of the emblematic culture of the Baroque period in Navarre
Long-Term Outcome After Intraoral Removal of Large Submandibular Gland Calculi
No full textObjectives/Hypothesis: To evaluate the long-term outcome of intraoral removal of large submandibular gland calculi. Study Design: Retrospective cohort study. Methods: A retrospective review (1995-2008) of 118 patients with submandibular calculi >= 10 mm treated by intraoral surgical removal with preservation of the salivary gland. Results: Calculi were completely removed in 103/118 (87.3%) cases, partially removed in 14/118 (11.9%), with failure to remove any fragments in only 1/118 (0.8%). After a mean follow-up of 42 months, 101/118 (85.6%) cases remained asymptomatic, 17/118 (14.4%) cases had modest obstructive or infective symptoms, 4/118 (3.4%) cases suffered recurrent stones, and in 1/118 (0.8%) case persistent symptoms dictated salivary gland removal. Conclusions: The data suggest that the majority of large submandibular gland calculi can be removed by gland-preserving procedures retaining an asymptomatic salivary gland. This casts doubt on the commonly held premise that salivary stones normally lead to chronic sialoadenitis, which is the basis for the current policy of sialoadenectomy.http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000277540200017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=8e1609b174ce4e31116a60747a720701Medicine, Research & ExperimentalOtorhinolaryngologySCI(E)PubMed8ARTICLE5964-96612
Convalescent plasma therapy in aHUS patient with SARS-CoV-2 infection
No full textEndotheliosis, thrombotic microangiopathy and complement system over activation have been described as pathologic features of tissue damage in the setting of coronavirus disease. Interestingly, complement-mediated cell injury is also a typical feature of atypical Hemolytic Uremic Syndrome. Indeed, a growing body of literature has described a higher risk of microangiopathy recurrence, in aHUS patients who test positive for SARS-CoV-2. The correct clinical and therapeutic management patients with a history of HUS and SARS-CoV-2 infection is not well established.We report a case of SARS-CoV-2 infection in an aHUS patient who did not develop a recurrence of the disease and that was successfully treated with convalescent immune plasma therapy
The Legacy of Iconoclasm: religious war and the relic landscape of Tours, Blois and Vendôme, 1550-1750
No full textThis study explores the process of physically rebuilding, renewing and reinventing the relic landscape in the regions around Tours, Blois and Vendôme following the widespread iconoclastic damage of the French religious wars. The author takes a long-term perspective exploring developments over two hundred years, from the mid-sixteenth through to the mid-eighteenth centuries. The book explores what the physical renewal of the landscape can tell us about evolving beliefs and practices concerning relics during the Catholic Reformation and what reconstruction activities reveal about the meaning and experience of relic veneration. It pays particular attention to how the relic landscape evolved through relic translations and how communities that oversaw relic shrines remembered the iconoclastic acts of the religious wars through liturgical and ritual commemorations, memorials, artistic renderings, oral traditions and written accounts.Publisher PD
Venetian cardinals at the Papal Court during the pontificates of Sixtus IV and Innocent VIII : 1471-1492
No full textThe histories of particular cities and states within that myriad-faceted
slice of civilisation, the Renaissance in Italy, have received
more scholarly attention than have the diplomatic, ecclesiastical and
cultural connections between them. This study is part of a balance-redressing
process. Senior clerics traversed frontiers, owing
allegiance to their native state, their benefices and, above all, to
the Papacy. The purpose of this exploration of the curial careers of
four later quattrocento Venetian cardinals is essentially twofold : to
account for relations between Venice and the Papacy with reference to
individuals who were at once Venetian patricians and princes of the
Church; and to examine the cardinals' responses to this situation in
terms of political, ecclesiastical and cultural patronage. Where did
their loyalty lie? To Venice, with its perennial suspicion of the
Church and peculiar notion of the characteristics of a Venetian
cardinal? Or to the Pope, expressing overt hostility towards the
Republic in the War of Ferrara and placing it under an interdict?
Chapter one sets Merco Barbo, Pietro Foscari, Giovanni Michiel and
Giovanni Battista Zeno in a Venetian context. Chapters two and three
chart relations between the two powers, from the exposure of Cardinal
Zeno's involvement in a scheme to transmit Venetian state secrets to
Rome in exchange for ecclesiastical preferment, through to Ermolao
Barbaro's controversial appointment to the patriarchate of Aquileia,
via the short-lived Papal-Venetian league negotiated by Cardinal
Foscari in 1480. The fourth chapter considers their proximity to the
Supreme Pontiff and how their material fortunes varied under popes
Sixtus and Innocent, after which an assessment of the nature, extent
and effectiveness of their patronage is divided between chapters five
and six, focussing pa.rticularly on Venetian connections. Despite
diverging careers, it is concluded that all were bound by variations
of the Venetian inheritance
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
No full textBackground: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
No full textBackground: Sparsentan, a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus irbesartan, an angiotensin II receptor blocker, at 36 weeks (primary endpoint) in patients with immunoglobulin A nephropathy in the phase 3 PROTECT trial's previously reported interim analysis. Here, we report kidney function and outcomes over 110 weeks from the double-blind final analysis.
Methods: PROTECT, a double-blind, randomised, active-controlled, phase 3 study, was done across 134 clinical practice sites in 18 countries throughout the Americas, Asia, and Europe. Patients aged 18 years or older with biopsy-proven primary IgA nephropathy and proteinuria of at least 1·0 g per day despite maximised renin-angiotensin system inhibition for at least 12 weeks were randomly assigned (1:1) to receive sparsentan (target dose 400 mg oral sparsentan once daily) or irbesartan (target dose 300 mg oral irbesartan once daily) based on a permuted-block randomisation method. The primary endpoint was proteinuria change between treatment groups at 36 weeks. Secondary endpoints included rate of change (slope) of the estimated glomerular filtration rate (eGFR), changes in proteinuria, a composite of kidney failure (confirmed 40% eGFR reduction, end-stage kidney disease, or all-cause mortality), and safety and tolerability up to 110 weeks from randomisation. Secondary efficacy outcomes were assessed in the full analysis set and safety was assessed in the safety set, both of which were defined as all patients who were randomly assigned and received at least one dose of randomly assigned study drug. This trial is registered with ClinicalTrials.gov, NCT03762850.
Findings: Between Dec 20, 2018, and May 26, 2021, 203 patients were randomly assigned to the sparsentan group and 203 to the irbesartan group. One patient from each group did not receive the study drug and was excluded from the efficacy and safety analyses (282 [70%] of 404 included patients were male and 272 [67%] were White) . Patients in the sparsentan group had a slower rate of eGFR decline than those in the irbesartan group. eGFR chronic 2-year slope (weeks 6-110) was -2·7 mL/min per 1·73 m2 per year versus -3·8 mL/min per 1·73 m2 per year (difference 1·1 mL/min per 1·73 m2 per year, 95% CI 0·1 to 2·1; p=0·037); total 2-year slope (day 1-week 110) was -2·9 mL/min per 1·73 m2 per year versus -3·9 mL/min per 1·73 m2 per year (difference 1·0 mL/min per 1·73 m2 per year, 95% CI -0·03 to 1·94; p=0·058). The significant reduction in proteinuria at 36 weeks with sparsentan was maintained throughout the study period; at 110 weeks, proteinuria, as determined by the change from baseline in urine protein-to-creatinine ratio, was 40% lower in the sparsentan group than in the irbesartan group (-42·8%, 95% CI -49·8 to -35·0, with sparsentan versus -4·4%, -15·8 to 8·7, with irbesartan; geometric least-squares mean ratio 0·60, 95% CI 0·50 to 0·72). The composite kidney failure endpoint was reached by 18 (9%) of 202 patients in the sparsentan group versus 26 (13%) of 202 patients in the irbesartan group (relative risk 0·7, 95% CI 0·4 to 1·2). Treatment-emergent adverse events were well balanced between sparsentan and irbesartan, with no new safety signals.
Interpretation: Over 110 weeks, treatment with sparsentan versus maximally titrated irbesartan in patients with IgA nephropathy resulted in significant reductions in proteinuria and preservation of kidney function
